Final Thoughts: A Tool, Not a Trend From an endocrinologists perspective, GLP-1 medications represent a major advancement in treating diabetes and obesity
Be cautious when medical necessity is secondary to memberships, prepaid bundles, standard cocktails, or promises of energy and immunity
Be aware, however, that if your insurance covers Ozempic (FDA-approved for diabetes), it may not approve Wegovy (FDA-approved for weight loss) and vice versa." Another exception is Mounjaro, which Mattingly says is a mixture of two active medications, because there currently is no substitute for it
Author: Thomas Cullen Source: Ti Insight Ti Pro is the definitive platform for logistics and transport market data, provider intelligence, and strategic analysis
doi: 10.1089/thy.2017.0395 78 ZhaoH.YuanL.ZhuD.SunB.DuJ.WangJ